PYRUKYND

This brand name is authorized in United States. It is also authorized in Austria, Croatia, France, Ireland, Italy, Lithuania.

Active ingredients

The drug PYRUKYND contains one active pharmaceutical ingredient (API):

1	Mitapivat UNII N4JTA67V3O - MITAPIVAT SULFATE
	Mitapivat is a pyruvate kinase activator and acts by directly binding to the pyruvate kinase tetramer. The red blood cell (RBC) form of pyruvate kinase (PKR) is mutated in PK deficiency, which leads to reduced adenosine triphosphate (ATP) levels, shortened RBC lifespan and chronic haemolysis. Mitapivat improves RBC energy homeostasis by increasing PKR activity.
	Read more about Mitapivat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PYRUKYND Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B06AX04		B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AX Other hematological agents
Discover more medicines within B06AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	60597386, 60728501, 60861124, 62256896, 63733756
IT	Agenzia del Farmaco	050445016, 050445028, 050445042, 050445055, 050445067
LT	Valstybinė vaistų kontrolės tarnyba	1095946, 1095947, 1095948, 1095949, 1096042, 1096043
US	FDA, National Drug Code	71334-205, 71334-210, 71334-215, 71334-220, 71334-225, 71334-230